Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the funding opportunity database SPIN. Click here for more information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on GCO’s Funding Opportunities page and on the ORS Research Roadmap COVID-19 Funding Opportunities page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in The Conduit newsletter.

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

The Grants and Contracts Office

---

<table>
<thead>
<tr>
<th>SPIN ID Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>093351 FCO -- AMENDMENT -- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)</td>
<td>Department of Health &amp; Human Services</td>
<td>BARDABAA</td>
<td>31-Oct-2021</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: BARDA-BAA@hhs.gov
Contact Telephone: Link to sponsor website
Contact Email: Link to program URL
Sponsor Website: 31-Oct-2021
Synopsis: Description We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur. The latest BARDA Broad Agency Announcement (BAA) is amendment 16 posted on April 24, 2020. Note: COVID-19 response related Areas of Interest includes: AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), including Serology Tests AOI 8.3 COVID-19 Vaccine AOI 9.2 COVID-19 Therapeutics AOI 9.3 Immunomodulators or therapeutics targeting lung repair AOI 9.5 Pre-exposure and...
post-exposure prophylaxis AOI 10 Respiratory protective devices AOI 11 Ventilators AOI 17 Advanced Manufacturing Technologies All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA clarified the language for rolling review of COVID-19 response related full proposals. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table. The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter. Additional betasam.gov information Notice Id 0bba3967c3404799ab043da9b3456ed Source https://betasam.gov/app/0bba3
Note: This link might not be valid after archive date below. Archive Date 10/31/2020

2. COVID-19 Fund to Retain Clinical Scientists Request for Applications
Duke (Doris) Charitable Foundation
22-Jun-2021 Not Specified

Contact Name
Contact Telephone 212-974-7000
Contact Email ddcf@aibs.org
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 22-Jun-2021 [LOI/Pre-App], 20-Jul-2021

Synopsis
The Doris Duke Charitable Foundation, together with the Burroughs Wellcome Fund, Rita Allen Foundation, and Walder Foundation, believe that this is a key moment to accelerate long needed culture change for academia to become more inclusive of scientists with family caregiving needs. The sponsors have come together to support and spotlight changes at the institutional level that can support scientists with family caregiving needs, focusing on early-career physician scientists working at U.S. medical schools. This is a workforce ripe to benefit from institutional action and proximate to the public health concerns that are front and center during the pandemic. Building on the promising outcomes of the Doris Duke Fund to Retain Clinical Scientists program, the Doris Duke Charitable Foundation and its partners are allocating up to $10 million to award one-time institutional grants of $500,000 total direct cost plus 10% indirect costs over two years to U.S. medical schools that are evolving to strengthen policies, practices, and processes to support the research productivity of early-career faculty with family caregiving responsibilities. The majority of the grants are earmarked to support institutional programs providing research supplements for physician scientists working on clinical research projects whose productivity is being impacted by family caregiving responsibilities increased by COVID-19. The goal of the research supplements will be to enable recipients to regain research productivity and momentum and to prevent their attrition from research. Supplement candidates must be early faculty who are working on significant biomedical problems. They must have active financial support, whether intra or extramural, for their main research and be on a clear trajectory to a successful independent research career. Importantly, they must be able to articulate how the supplement would enable them to maintain research productivity in light of family caregiving responsibilities augmented by COVID-19. The supplemental funds from the Fund to Retain Clinical Scientists would typically be used to support temporary technical assistance. Funding has been earmarked to support at least two grants to minority-serving U.S. medical schools.

3. RFA-DA-22-005 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed)
National Institute on Drug Abuse/NIDHHS
RFA-DA-22-005 14-Sep-2021 [Optional] 275,000 USD

Contact Name Vani Pariyadath, Ph.D.
Contact Telephone 301-443-3209
Contact Email vanipariyadath@nih.gov
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 14-Sep-2021 [Optional] [LOI/Pre-App], 14-Oct-2021

Synopsis
This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-007.

4. RFA-DA-22-024 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed)
National Institute on Drug Abuse/NIDHHS
RFA-DA-22-024 14-Sep-2021 Not Specified
Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)

Contact Name: Vani Pariyadath, Ph.D.
Contact Telephone: 301-443-3209
Contact Email: vanipariyadath@nih.gov
Sponsor Website: Link to program URL

Program URL: Link to program URL
Deadline Dates (ALL): 14-Sep-2021 [Optional] [LOI/Pre-App], 14-Oct-2021

Synopsis: This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Applicants with exploratory and high-risk research projects should consider applying to the companion R01 announcement RFA-DA-22-030.

5. RFA-DA-22-030 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required)

Contact Name: Vani Pariyadath, Ph.D.
Contact Telephone: 301-443-3209
Contact Email: vanipariyadath@nih.gov
Sponsor Website: Link to program URL

Program URL: Link to program URL
Deadline Dates (ALL): 14-Sep-2021 [Optional] [LOI/Pre-App], 14-Oct-2021

Synopsis: This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applicants with projects testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-030.


Contact Name: Priscilla Grant, JD
Contact Telephone: 301-594-8412
Contact Email: pg38h@nih.gov
Sponsor Website: Link to program URL

Program URL: Link to program URL
Deadline Dates (ALL): Continuous Submission

Synopsis: NIMHD is soliciting supplements to active NIMHD grants and cooperative agreements to support research on HIV/AIDS in NIH-designated populations that experience health disparities, including Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. The purpose of this NOSI is to emphasize the continued importance of conducting research on HIV/AIDS that will further the EHE effort, including but not limited to research on how the COVID-19 pandemic and structural racism and discrimination affect HIV risk, prevention, and treatment among populations that experience health disparities.

7. Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

Contact Name: Larissa Aviles-Santa, MD, MPH
Contact Telephone: 301-827-6924
Contact Email: avilesantanl@mail.nih.gov
Sponsor Website: Link to program URL

Program URL: Link to program URL
Deadline Dates (ALL): 05-Oct-2021

Synopsis: NIMHD is soliciting supplements to active NIMHD grants and cooperative agreements to support research on HIV/AIDS in NIH-designated populations that experience health disparities, including Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. The purpose of this NOSI is to emphasize the continued importance of conducting research on HIV/AIDS that will further the EHE effort, including but not limited to research on how the COVID-19 pandemic and structural racism and discrimination affect HIV risk, prevention, and treatment among populations that experience health disparities.
Program URL
Link to program URL

Deadline Dates (ALL)
05-Oct-2021, 07-Jan-2022, 05-Feb-2022, 07-May-2022, 05-Jun-2022, 07-Sep-2022,
05-Oct-2022, 07-Jan-2023, 05-Feb-2023, 07-May-2023, 05-Jun-2023, 07-Sep-2023,
07-Jan-2024, 05-Feb-2024, 07-May-2024, 05-Jun-2024, 07-Sep-2024

Synopsis
This initiative will support innovative research to develop, test and evaluate multi-
level/multi-component strategies (including models of health care) to effectively
adapt and implement comprehensive clinical care for individuals with Type 2 diabetes
mellitus from populations with health disparities concordant with recommended and
evidence-based guidelines.

8. 104370 Rural Health Clinic Vaccine Confidence Program
Office of Rural Health Policy/HRSA/DHHS
HRSA-21-142 23-Jun-2021 50,000 USD

Contact Name Lindsey Nienstedt
Contact Telephone 301-443-0835
Contact Email RHCVaxConfidence@hrsa.gov
Sponsor Website Link to sponsor website
Program URL
Deadline Dates (ALL) 23-Jun-2021

Synopsis
The Health Resources and Services Administration (HRSA) is accepting applications for
the fiscal year (FY) 2021 Rural Health Clinic Vaccine Confidence (RHCVC) Program. The
purpose of this program is to address COVID-19 related health equity gaps and improve
health care in rural areas by engaging Rural Health Clinics (RHCs) to improve vaccine
confidence and counter vaccine hesitancy in rural communities.